GOLGA4 Knockout SK-HEP-1 Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population derived from the SK-HEP-1 human liver adenocarcinoma line. This heterogeneous model ablates GOLGA4 function across a mixed cell pool, providing a system to probe Golgi and secretory pathway dynamics in hepatocellular carcinoma (HCC) while preserving natural clonal variability, thus mirroring the genetic and phenotypic diversity of tumor cell populations.
The SK-HEP-1 host cell line, derived from ascitic fluid of a liver adenocarcinoma patient, is a widely used model for HCC and translational oncology research. These tumorigenic epithelial cells exhibit invasive characteristics, making them suitable for dissecting mechanisms of progression, metastasis, and drug resistance. They retain key features such as xenograft tumor formation and epithelial-mesenchymal transition, processes mechanistically linked to secretory pathway remodeling.
GOLGA4 encodes a cis-Golgi golgin tethering factor that captures transport vesicles, facilitating membrane fusion and organelle architecture maintenance. It interacts with activated RAB GTPases, notably RAB6A and RAB2A, and with ARF1, engaging golgins GOLGA5 and GOLGA1, and linking to cytoskeletal and regulatory proteins such as MACF1 and TBC1D23. This multimeric complex orchestrates COPI-coated vesicle docking and SNARE-mediated bilayer fusion, sustaining Golgi ribbon cohesion and processive secretory flux. Disruption of GOLGA4 therefore impairs retrograde and anterograde trafficking, potentially altering surface expression of receptors and adhesion molecules critical for tumor cell behavior.
In SK-HEP-1 HCC cells, loss of GOLGA4 disrupts Golgi organization and vesicular trafficking, processes frequently dysregulated to support enhanced secretion of pro-invasive factors and drug resistance proteins. This polyclonal knockout population enables robust functional studies of impaired Golgi tethering on tumor cell migration, viability, and secretory capacity. By preserving intrinsic clonal diversity, it facilitates investigation of heterogeneous responses to secretory pathway inhibition, shedding light on how Golgi dysfunction may contribute to metastatic dissemination and therapeutic evasion in liver cancer.
Researchers can apply these cells in immunofluorescence and electron microscopy to visualize Golgi fragmentation, and in secretion reporter assays to quantify trafficking deficits. Cell migration and viability assays assess the impact of GOLGA4 loss on metastatic potential and sensitivity to agents such as sorafenib or doxorubicin. Western blotting enables monitoring of Golgi proteins including GOLGA5, RAB6A, and SNARE components. The model is also suited to organelle-focused functional genomics screens and evaluation of secretory pathway-targeted therapies. For further information and order inquiries, please contact Ascent Research.
